Ripretinib is currently in clinical development for the treatment of advanced gastrointestinal stromal tumours (GIST). GIST is a rare type of cancer that commonly develops in the gastrointestinal tract. The cause of GIST is unknown but the majority of cases are associated with a certain gene mutations that produce abnormal enzymes. GIST are very aggressive, can spread quickly to other parts of the body (metastatic) and are not easily removed surgically (unresectable). There are currently no approved therapies for patients with GIST who have exhausted treatment options with approved first, second, and third-line agents.
Ripretinib is a drug specifically designed to stop the abnormal and overactive enzymes in GIST cells from working, including forms that cannot be blocked by other medicines. Stopping these enzymes is expected to slow down the growth of the tumours and reduce symptoms of the disease. If licensed, ripretinib will offer a fourth-line treatment option for patients with unresectable or metastatic GIST who have exhausted all other approved treatment options.
Atezolizumab is in clinical development, in combination with platinum-based chemotherapy, for the treatment of patients with locally advanced or metastatic urothelial cancer, who have received no prior systemic therapy (a drug which travels through the bloodstream and affects the whole body). Urothelial cancer, a subset of bladder cancer, occurs on the lining of the bladder, and other parts of the urinary system. In advanced urothelial cancer, the cancer has grown into deeper layers including connective tissue or muscle. Metastatic urothelial cancer occurs when the cancer has spread to other parts of the body, such as the liver or bones.